Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Rating of “Moderate Buy” by Brokerages

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) has earned an average rating of “Moderate Buy” from the eleven brokerages that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $45.00.

A number of research analysts have weighed in on CRBP shares. Mizuho set a $39.00 price target on Corbus Pharmaceuticals in a research note on Wednesday, October 29th. Wedbush increased their price objective on Corbus Pharmaceuticals from $31.00 to $38.00 and gave the company an “outperform” rating in a report on Monday, October 20th. Lifesci Capital raised shares of Corbus Pharmaceuticals to a “strong-buy” rating in a research note on Saturday, July 12th. Piper Sandler restated an “overweight” rating and set a $51.00 target price on shares of Corbus Pharmaceuticals in a report on Monday, October 20th. Finally, Benchmark reiterated a “reduce” rating on shares of Corbus Pharmaceuticals in a research note on Monday, October 20th.

Insider Buying and Selling at Corbus Pharmaceuticals

In other Corbus Pharmaceuticals news, CEO Yuval Cohen sold 8,973 shares of the company’s stock in a transaction on Monday, October 27th. The shares were sold at an average price of $17.14, for a total value of $153,797.22. Following the transaction, the chief executive officer directly owned 138,187 shares in the company, valued at $2,368,525.18. The trade was a 6.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Sean F. Moran sold 12,981 shares of the firm’s stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $17.02, for a total transaction of $220,936.62. Following the sale, the chief financial officer owned 73,313 shares of the company’s stock, valued at approximately $1,247,787.26. This represents a 15.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 41,674 shares of company stock valued at $713,870 in the last ninety days. Insiders own 3.60% of the company’s stock.

Institutional Trading of Corbus Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Corton Capital Inc. acquired a new position in Corbus Pharmaceuticals in the 2nd quarter valued at $86,000. Marshall Wace LLP acquired a new stake in shares of Corbus Pharmaceuticals during the second quarter worth $137,000. Baker Avenue Asset Management LP bought a new stake in shares of Corbus Pharmaceuticals in the second quarter valued at about $138,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Corbus Pharmaceuticals in the second quarter valued at about $141,000. Finally, Stonepine Capital Management LLC acquired a new position in shares of Corbus Pharmaceuticals in the first quarter valued at about $186,000. 64.64% of the stock is owned by institutional investors and hedge funds.

Corbus Pharmaceuticals Stock Up 0.8%

NASDAQ:CRBP opened at $10.52 on Friday. The company has a market cap of $128.92 million, a P/E ratio of -2.21 and a beta of 2.69. Corbus Pharmaceuticals has a twelve month low of $4.64 and a twelve month high of $20.56. The business has a 50 day moving average price of $13.26 and a two-hundred day moving average price of $10.03.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.